September 27, 2021 7:39am

Brace for the final week of September being volatile

The Biostage Chronicles:  Can investors hold management and its board responsible for negligence <failure to produce the required discovery> in their latest misstep of their insurance carrier dropping coverage and legal reimbursement for legal costs in the on-going terminal death suit?

Pre-open indications: 3 BUYs and 2 SELLs

What I provide is an intelligence daily. RMi outlines the prelude to the daily dose of facts and objectivity!

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

Dow futures are UP +0.20% (+69 points), S&P futures are DOWN -0.08% (-4 point) and NASDAQ futures are DOWN -0.50% (-77 point)

 

Pre-open index futures are mixed and slipping on Monday,

European stocks rose, with German election results seen eliminating a key market risk for investors in the region,

Asia-Pacific stocks were mixed linked to the Evergrande bond interest risk of payment.

 

Henry’omics:

Brace for a week of a volatility; also, drop-in the possibility of a potential government shutdown to end the week.

September is living up to its reputation for volatility and weakness as major averages have all registered modest losses.

 

If you didn’t remember what happen at Friday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

Q3/21:

  • September, 1 holiday, 9 positive and 7 negative close
  • August - 12 positive and 10 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining SELL:

Biostage (BSTG)Friday closed flat at 3.26 with 62 shares traded after Thursday closed up +$0.06 with 839 shares traded, Wednesday closed down -$0.45 with 3,833 shares traded, Tuesday’s +$0.25 with 654 shares traded following last Monday closing down -$0.26 to $3.40 with 563 shares traded.

  • Question: Could negligence (not turning over documents and a sanction being initiated) be the reason BSTG’s insurance company dropped coverage and legal reimbursement for the terminal death suit legal costs?

 

SELL:

Editas Medicine (EDIT) closed down -$3.36 to $58.71 after Thursday’s +$2.96 to $62.07, Wednesday’s +$0.43, Tuesday’s $58.68 and last Monday’s $58.20 with a negative -$0.21 or -0.36% pre-market indication with a 52-week change of +100.48%.

 

BUY:

Applied Genetic Technologies (AGTC) closed down -$0.19 to $3.23 and has a positive +$0.21 or +$6.50% pre-market indication after Thursday’s release of earnings for the Q and FY21.

CRISP Therapeutics (CRSP) closed down -$4.82 to $116.43 after Thursday’s +$3.44 to $121.25 after Wednesday’s +$0.56 to $117.81, Tuesday’s +$0.78 to $117.25 and last Monday’s down -$8.05 to $116.47 and has a positive +$0.57 or +0.49% pre-market indication.

Global Blood Therapeutics (GBT) closed down -$0.95 to %25.57 after Thursday’s up +$0.38 to $26.52, Wednesday’s -$0.86 to $26.14, Tuesday’s -$0.10 to $27.00 and Monday’s $27.10 with a positive +$1.177 or +4.58% pre-market indication.

 

 

The BOTTOM LINE: this week is a period of volatility as the quarter (Q3) comes slowly to an end.

Friday pared a lot of gains as the stock market rally last week went nowhere. The major indexes tumbled on Monday, but then roared back, with a slew of leading stocks flashing buy signals.

After a “scrubbing” the sector could use a little polish on their bones!

Not yielding, I keep reinforcing the theme that increased stock market volatility suppresses the stem, cell and gene therapy sector.

A quote from Investor’s Business Daily, “This week shows the importance of being flexible. On Monday, most investors probably should have been selling — ideally, they were scaling back in the prior two weeks, taking some partial profits. After Monday, the risks were high that the market was going to fall into a correction. As it turned out, the market rebounded. By Thursday at least, investors should have been taking advantage of the large number of buying opportunities. Many are still actionable, while a number of stocks are on the cusp.”

I maintain, the recent stem, cell and gene therapy sector investors should be a bit more defensive, limiting new buys and perhaps curtailing overexposure to electronic trading risks.

Theme is uncertainty, more likely to me: skepticism …

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.